STANISLAUS CONNECTIONS

Working For Peace, Justice, and A Sustainable Environment

June, 2001

A Modesto Peace/Life Center Publication

HIV/AIDS in Africa

Aids in Africa: A GENERATION AT RISK

The African AIDS crisis staggers the imagination. Six thousand Africans die daily, making it the worst infectious disease calamity since the Plague of the Middle Ages. More persons will die of AIDS in Africa over the next decade than have died from all the world’s wars of the 20th century. Many AIDS victims have done nothing more harmful than enter the world — 12.1 million African children have been orphaned by AIDS. For them the tragedy is only beginning, since many have or are likely to contract the disease. As an entire generation disappears before our eyes, church groups, private agencies and caring people worldwide and in Africa struggle to find effective responses to this catastrophe.

... We are one world, and these children are our children. Their destiny is our destiny. Each of us can make a difference. Each of us can help save lives. Let us wage this holy war together. And for the sake of our children, we will win. — Bishop Desmond Tutu

AN AFRICAN PLAGUE

Malawian women with AIDS.

The National Community of Women Living with AIDS in Uganda created a special project — the Memory Book. Mothers write their life story in the book with family photos and talk about where they came from, experiences they’ve had.

“And they talk about their children because, you see, they want to leave these books for their kids, so that when they are gone — and they know that day is coming — their children will have this memory book to look at. I sat on the porch there as two mothers read to me from their books. I realized then that I was in a nation that had turned into a hospice.” — Sen. Richard Durbin

A GENERATION OF ORPHANS

Without significant intervention, by 2010 there will be 40 million AIDS orphans in Africa, most of whom will have grown up with little or no social structure. That is equal to all the children attending public schools in the USA today.

Orphans are at far greater risk of malnutrition and unlikely to receive the health care or education they need. They are also more likely to engage in hazardous labor, including commercial sex work, which in turn exposes them to greater risk of HIV infection.

AIDS has wiped out decades of progress in improving the lives and health of families in Africa — infant mortality is doubling, child mortality is tripling, and life expectancy is plummeting by twenty years or more.

Poverty-stricken African health systems are being overwhelmed by AIDS. Up to 50 percent of hospital beds are occupied by HIV/AIDS patients in many parts of sub-Saharan Africa.

CONTRIBUTING FACTORS:

Status of Women: Economic dependency and social norms make it hard for women and girls to deny men sex. Women account for 55 percent of the continent’s HIV infections. Teenage girls suffer 5 to 6 times the infection rates of boys because older men prey on them. At the same time, women and girls tend to bear the main burden of caring for sick family members, and often have less care and support when they are infected.

Poverty/Debt: 95 percent of Africans infected with HIV/AIDS live in abject poverty, with no hope of obtaining the new drugs that patients in developed countries use to combat the virus and lead comparatively normal lives. Half of Africa’s population lack access to safe drinking water, two-thirds lack access to adequate sanitation. African nations are forced to spend four times more on repaying their foreign debt than on health care or education.

Wars/Refugees: Soldiers often visit commercial sex workers — 90 percent of whom are believed to have AIDS. Civil conflict, displaced populations and increasing interventions by the armed forces of African nations further spread the disease. People are six times more likely to contract HIV in a refugee camp than in the outside population.

Fear and Denial: The stigma associated with AIDS prevents open discussion and diminishes support systems. Thandiwe Mwandla, a South African woman with AIDS, found that when her diagnosis was known, no one would buy her sugar cane or anything else she had touched. Her neighbors walked around her. She notes, “We get sick, and we get poor, and we die lying to ourselves.”

Cultural Factors: Polygamy and unsafe sexual practices are key factors. Since most men are not tested, they can unknowingly spread the disease. Many men believe sex with a virgin will cure AIDS, prompting them to target younger and younger girls. Compounding the problem is a common belief among women that if a man looks healthy, he couldn’t have AIDS.

THE ROAD TO RECOVERY

My friend with AIDS is still my friend. --South African Bumper sticker

Despite staggering statistics, significant progress is being made against AIDS by churches, governments and community organizations banding together to break the silence, challenge behavior, and provide basic care to those in need.

A tree of hope: Research conducted by Church World Service (CWS) in Senegal has demonstrated that the Moringa tree, native to tropical regions, is a fountain of vitamins and minerals. Gram for gram, Moringa leaves contain three times the iron of spinach, four times the vitamin A of carrots, seven times the vitamin C of oranges. It can also be used to clarify water, treat diabetes, and cure skin infections. CWS has launched a major initiative to promote the use of Moringa as a nutritional supplement throughout Africa.

Leading the way: Ethiopian community-based and religious organizations are at the forefront of the fight against AIDS in that country. For example, the Ethiopian Orthodox Church (a CWS partner) organizes public rallies, youth workshops, counseling, and street theater to raise awareness and encourage abstinence from premarital sex. Since those carrying the disease are often discriminated against, sometimes losing their employment, the church provides money and training for income-generating projects. They have joined forces with Catholics, Evangelicals and Muslims to create a joint interfaith effort to curb the disease.

“AIDS doesn’t care about what your religion is,” commented one resident of Rakai, a Ugandan province with one of the highest HIV incidence rates in the world. In the face of desolate villages, fallow fields and abandoned orphans, Lutheran World Federation initiated a rehabilitation and development program in 1992. Clinics were established, roads and schools repaired, and school teachers were educated as health instructors. But to ensure full community participation, local religious leaders needed to cooperate. Overcoming generations of tension, the Muslim District Khaddi and the Anglican and Catholic bishops agreed to meet, pray and work together. The number of HIV/AIDS cases has dropped substantially, and their model program is now shown to visitors from around the world.

WHAT CAN I DO?

SOURCES FOR FURTHER LEARNING

Big Pharma and the global response to HIV/AIDS

By RUSSELL MOKHIBER and ROBERT WEISSMAN

One of the perquisites of power is that the powerful can always command a fresh start. Past crimes and misdemeanors, and even current misdeeds, are not held against them.

Consider the case of the pharmaceutical industry and the issue of access to HIV/AIDS and other essential medicines.

The rich countries are now, belatedly, gearing up to commit some substantial monies to address HIV/AIDS in Africa and elsewhere in the developing world. The brand-name pharmaceutical companies are jockeying for a central role in determining how those monies are spent. And, unless sufficient public opposition emerges, they are likely to secure it.

There is now no serious dispute that the brand-name pharmaceutical companies have worked overtime to deny poor countries access to lifesaving medicines.

The industry insistence in maintaining its lawsuit challenging South Africa’s Medicines Act helped forge a broad, worldwide consensus — from the New York Times to the European Parliament — against the industry’s role in interfering with poor countries’ efforts to promote access to essential medicines. International condemnation forced the industry to back down in the suit, but the South Africa case was only one of many instances where the industry has played a pernicious role. Big Pharma’s obsession has been to block the introduction of generic competition — which has the potential to bring drug prices down by 95 percent or more — and it has employed misleading propaganda campaigns, threats of litigation, promises of trade sanctions, and new trade agreements to advance its aims.

Against this backdrop comes a set of proposals for a global AIDS fund, or a global tropical disease fund. In late June, the United Nations will hold a special session on HIV/AIDS. Then the elite rich countries, grouped together in the G8, will meet in Genoa, Italy, in July. There is widespread expectation that the rich countries will agree to a framework for a new fund, and make preliminary dollar commitments. UN Secretary General Kofi Annan has requested contributions of $7 billion to $10 billion per year. The United States is expected to announce a $200 million commitment shortly.

How the fund will be governed and operated remains very unclear.

One possible starting point is a new, U.S.-initiated fund, housed at the World Bank. The World Bank AIDS Trust Fund was created by Congressional action last year, and the United States has allocated $20 million for the fund. This fund was intended to galvanize international donations, but they have not materialized, and some thought the fund would never get off the ground. However, Kofi Annan’s proposal for a global fund sounded very similar to the World Bank AIDS Trust Fund, leading some to think the World Bank entity would be revamped and become the big global fund.

That makes governance of the fund very important. The U.S. Treasury Department is in charge of establishing the charter for the World Bank AIDS Trust Fund. The Treasury Department’s proposal envisions a governing board made up of donors, with some participation by recipient countries. “Donors” would include not just governments, but private parties — meaning not just private foundations, but private corporations E including the drug companies. Under the Treasury Department proposal, for $5 million contributions, the drug companies would be able to buy themselves seats on the Trust Fund’s governing board.

This is a morally outrageous proposal. There are many parties to blame for the horrible toll taken by the AIDS pandemic in poor countries (with as many as one in three adults now HIV-positive in some African countries, and virtually all of the HIV-positive people certain to die from AIDS unless treatment costs are radically reduced), but the drug companies are hugely culpable. That they would be permitted a key role in directing the world’s belated response to the crisis dishonors the memories of the millions who have died preventable deaths from HIV/AIDS.

Underlying the moral argument are very practical considerations. Big Pharma participation on the governing body of new global fund would create an irresolvable, structural conflict of interest.

For example, a crucial decision for the new fund will be whether it buys drugs at best world prices, from multiple sources, including generics. The brand-name companies are intent on excluding generics, and the brand-name companies certainly should not have a role in the fund’s decision-making on this issue.

Suggestions that the brand-name companies could simply recuse themselves from such issues offer no solution. The brand-name companies should not be positioned to influence fellow board members. And lots of decisions the board will make — from matters relating to the mechanisms to deliver drugs, drug registration rules, preferred drug regimens, and much more — will involve issues where drug company conflicts will be pervasive, but may not be recognized.

If Big Pharma wants to redeem itself and be “part of the solution” to the AIDS pandemic, there is plenty it can do, starting with issuing licenses for its HIV/AIDS drugs to the World Health Organization, which could then contract with generic makers to provide cheap drugs for distribution in poor countries. But putting the industry in charge, or partially in charge, of the primary global response to HIV/AIDS — especially while the brand-name companies continue to place enormous obstacles in the way of the generic competition that could make AIDS drugs far more affordable and save millions of lives — would be unconscionable.

Russell Mokhiber edits the Corporate Crime Reporter. Robert Weissman edits the Multinational Monitor, and co-directs Essential Action, a corporate accountability group. They are co-authors of Corporate Predators: The Hunt for MegaProfits and the Attack on Democracy (Common Courage Press, 1999). Focus on the Corporation columns are posted at www.corporatepredators.org

(c) Russell Mokhiber and Robert Weissman. Reprinted with permission

HIV/AIDS: General Assembly to hold special June session.

The UN General Assembly will convene a special session from June 25 to 27, 2001 to address the global HIV/AIDS epidemic. According to the assembly, the issue is “a matter of urgency.”

In a unanimous resolution, the General Assembly declared it will examine HIV/AIDS in Africa, international funding and cooperation, the epidemic’s economic and social impacts and human rights implications. The resolution also asks UN Secretary-General Kofi Annan to submit a comprehensive report on the epidemic, the international response and an analysis of long-term impacts.

In addition, the resolution asks the General Assembly president to determine the form and involvement of civil society in the special session. The assembly specifically said people living with HIV/AIDS, nongovernmental organizations and the business sector, including pharmaceutical companies, should be involved.

For information, visit: http://www.un.org/ga/aids/, or call (212) 963-6870, Fax: (212) 963-0536; email: pascale@un.org